Arvinas Inc - Asset Resilience Ratio
Arvinas Inc (ARVN) has an Asset Resilience Ratio of 75.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arvinas Inc's Asset Resilience Ratio has changed over time. Check Arvinas Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Arvinas Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Arvinas Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $542.50 Million | 75.57% |
| Total Liquid Assets | $542.50 Million | 75.57% |
Asset Resilience Insights
- Very High Liquidity: Arvinas Inc maintains exceptional liquid asset reserves at 75.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arvinas Inc Industry Peers by Asset Resilience Ratio
Compare Arvinas Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Arvinas Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arvinas Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.57% | $542.50 Million | $717.90 Million | -10.46pp |
| 2024-12-31 | 86.03% | $938.90 Million | $1.09 Billion | +13.26pp |
| 2023-12-31 | 72.77% | $949.30 Million | $1.30 Billion | -15.82pp |
| 2022-12-31 | 88.59% | $1.12 Billion | $1.27 Billion | +0.43pp |
| 2021-12-31 | 88.16% | $1.39 Billion | $1.58 Billion | +74.19pp |
| 2020-12-31 | 13.97% | $100.20 Million | $717.40 Million | -76.09pp |
| 2019-12-31 | 90.06% | $271.66 Million | $301.64 Million | -2.59pp |
| 2018-12-31 | 92.65% | $184.64 Million | $199.28 Million | +80.30pp |
| 2017-12-31 | 12.35% | $8.26 Million | $66.85 Million | -67.96pp |
| 2016-12-31 | 80.31% | $30.47 Million | $37.94 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more